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(57) ABSTRACT 
The present invention describes a cardiac prosthetic system 
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component (515); a temporary valve (305) and a heart valve 
prosthesis (420) having a second releasably engaging com-
ponent ( 445) enabled to be securely coupled and uncoupled 
from the first releasably engaging component (515) of the 
harbor (415). 
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SYSTEMS AND METHODS FOR ENABLING 
HEART VALVE REPLACEMENT 
BENEFIT AND PRIORITY CLAIMS 
This application is a 35 U.S.C. §371 U.S. National Stage of 
International Application No. PCT /US2006/062199 filed 15 
Dec. 2006, which claims priority to and the benefit of U.S. 
Ser. No. 60/750,558, filed 15 Dec. 2005. All of said prior 
applications are hereby incorporated by reference in their 
entireties as if fully set forth below. 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
This application claims the benefit of U.S. Provisional 
Application No. 60/750,558, filed 15 Dec. 2005, which is 
hereby incorporated by reference in its entirety as if fully set 
forth below. 
FIELD OF THE INVENTION 
This invention refers generally to the field of heart valve 
replacement, and specifically to the implants tools and meth-
ods for preparing a native heart valve for a prosthesis and for 
providing a replaceable heart valve prosthesis. 
BACKGROUND OF THE INVENTION 
Cardiovascular disease accounts for nearly fifty percent of 
deaths in both the developed world and in developing coun-
tries. Indeed, the risk of dying from heart disease is greater 
than the risk from AIDS and all forms of cancer combined. 
Cardiovascular disease causes 12 million deaths in the world 
each year. It is the leading cause of death in the U.S., killing 
some 950,000 people each year. It also accounts for a signifi-
cant amount of disability and diminished quality oflife. Some 
60 million people in the U.S. alone have some form of heart 
disease. Therefore, a great need exists for the advancement of 
devices and procedures to cure, treat, and correct a wide 
variety of forms of heart disease. 
2 
passed to the body. When the left ventricle contracts in sys-
tole, the mitral valve closes and the oxygenated blood passes 
into the aorta rather than back through the mitral valve. On the 
other side of the heart, deoxygenated blood returns from the 
body and enters the heart through the right atrium. This 
deoxygenated blood flows through the tricuspid valve into the 
right ventricle. When the right ventricle contracts, the tricus-
pid valve closes and the deoxygenated blood is pumped 
through the pulmonary valve. Deoxygenated blood is 
10 directed to the pulmonary vascular bed for oxygenation, and 
the cardiac cycle repeats itself. 
The performance of the cardiac cycle by the various com-
ponents of the heart is a complex and intricate process. Defi-
ciency in one of the components of the heart or deficiency in 
15 the performance of the cardiac cycle most often leads to one 
or more of the numerous different types of heart disease. One 
prevalent heart disease condition is aortic valve regurgitation. 
Aortic valve regurgitation has many levels of severity. Aortic 
regurgitation is the diastolic flow of blood from the aorta into 
20 the left ventricle. Regurgitation is due to incompetence of the 
aortic valve or disturbance of the valvular apparatus (e.g., 
leaflets, annulus of the aorta) resulting in diastolic flow of 
blood into the left ventricular chamber. Incompetent closure 
of the aortic valve can result from intrinsic disease of the cusp, 
25 diseases of the aorta, or trauma. Aortic regurgitation may be a 
chronic disease process or it may occur acutely, presenting as 
heart failure. Diastolic reflux through the aortic valve can lead 
to left ventricular volume overload. 
FIG.1 provides an illustration ofa normal aortic valve 101. 
30 The perspective of the aortic valve 101 shown in FIG. 1 
provides a diagram of a dissected and flattened aortic valve 
101 to best illustrate its components. The aortic valve 101 has 
three cusps or leaflets, the left coronary cusp 105, the right 
coronary cusp 110, and the non-coronary cusp 115. These 
35 three cusps control the flow of blood from the left ventricle 
into the aorta, which ultimately conveys oxygenated blood to 
the tissues of the body for their nutrition. Located just above 
the three cusps, 105, 110, and 115, are the sinuses of the 
valsalva 125 and each sinus corresponds to each individual 
40 cusp. The origins of the coronary arteries are proximate the 
sinuses of the valsalva 125. As shown in FIG. 1, the orifice 
130 forthe right coronary artery is located just above the right 
coronary leaflet cusp 110. Similarly, the orifice 135 forthe left 
coronary artery is located just above the left coronary leaflet 
Normal heart function primarily relies upon the proper 
function of each of the four valves of the heart, which pass 
blood through the four chambers of the heart. The four cham-
bers of the heart include the right atrium and left atrium, the 
upper chambers, and the right ventricle and left ventricle, the 
lower chambers. The four valves, controlling blood flow in 
the chambers, include the tricuspid, mitral, pulmonary, and 
aortic valves. Heart valves are complex structures that rely on 
the interaction of many components to open and close the 50 
valve. More particularly, each of the four valves of the heart 
have leaflets, comprised of fibrous tissue, which attach to the 
walls of the heart and aid in controlling the flow of blood 
through the valve. The mitral valve has two leaflets and the 
tricuspid valve has three leaflets. The aortic and pulmonary 55 
valves have three leaflets that are more aptly termed "cusps," 
stemming from their half moon shape. 
45 cusp 105. Additionally, the aortic valve 101 is juxtaposed 
with the anterior mitral annulus 120. 
In a normal aortic valve 101, when the left ventricle con-
tracts in systole, the aortic valve cusps, 105, 110, and 115, 
open into the aorta and blood flows from the left ventricle into 
the aorta. When the left ventricle rests in diastole, the cusps, 
105, 110, and 115, meet and close, covering the area of the 
valve annulus. Therefore, the cusps, 105, 110, and 115, pre-
vent regurgitation, or backflow of blood, into the left ventricle 
during diastole. 
The aortic valve 101 is located in the aortic root of the aorta. 
The aortic root has two main components, the inner (aorto-
ventricular junction) and the outer (sino-tubular junction), 
which are considered the functional aortic annulus. It is this 
aortic annulus that supports the fibrous structures of the 
cusps, 105, 110, and 115. 
The cardiac cycle involves the pumping and distribution of 
both oxygenated and deoxygenated blood within the four 
chambers. In systole, or the rhythmic contraction of the heart 60 
cycle, blood that has been oxygenated by the lungs enters the 
heart into the left atrium. During diastole, or the resting phase 
of heart cycle, the left atrial pressure exceeds the left ventricle 
pressure; thus, oxygenated blood flows through the mitral 
valve, a one way inflow valve, into the left ventricle. The 65 
contraction of the left ventricle in systole pumps the oxygen-
ated blood through the aortic valve, into the aorta, and is 
As shown in FIG. 1, the function of the aortic valve, 
involves the complex interaction of numerous components. If 
one of the components or functions of the complicated inter-
action fails, then aortic valve regurgitation can result. For 
example, a bicuspid valve, calcification of the cusps, or steno-
sis or restricted motion of the cusps can lead to aortic regur-
gitation. Prolonged and/or severe aortic valve regurgitation 
US 8,568,473 B2 
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can lead to compensatory left ventricle dilation. Aortic valve 
regurgitation is a progressive condition that, if not corrected, 
can be fatal. 
In addition to aortic regurgitation, pulmonic regurgitation 
is highly prevalent heart disease that causes or contributes to 
increasing numbers of heart disease each year. Like aortic 
regurgitation, pulmonic regurgitation involves the incompe-
tence of the pulmonic valve and its failure to completely 
close. In a normal pulmonic valve, the right ventricle con-
tracts in systole and pumps blood through the open pulmonic 
valve into the pulmonary artery. Contrastingly, when the right 
ventricle rests in diastole, the pulmonic valve closes and 
prevents the backflow of blood into the right ventricle. In 
cases of pulmonic regurgitation, the pulmonic valve fails to 
completely close and permits a regurgitant flow ofblood from 
the pulmonary artery back into the right ventricle during 
diastole. This backflow of blood can overload the right ven-
tricle and lead to right ventricle dilation. 
There a large variety of methods available in the prior art to 
treat different types of valvular heart disease such as pul-
monic regurgitation and aortic regurgitation. A highly popu-
lar and successful method of treatment of these conditions 
involves the use of prosthetic cardiac valves, such as 
mechanical valves and bioprosthetic valves. 
The most commonly used replacement devices are 
mechanical and bioprosthetic valves, with homografts and 
autografts less commonly used. From 1990 to 2000, the 
breakdown of valve replacement percentages as indicated by 
the Society of Thoracic Surgery Registry for patients less than 
60 years of age with aortic valve disease was a follows: 
mechanical valves in 77% of patients, bioprosthetic valves in 
13%, homograftvalves in 5%, and the Ross procedure in 5%. 
4 
in conjunction with anticoagulation therapies, which reduces 
the quality of life of the patient and exposes them to risks 
associated with bleeding. 
Bioprosthetic valves are tissue valves made of animal tis-
sue (i.e. xenografts) and are easily and readily available. 
These were introduced in the early 1970s as an attempt to 
avoid some of the disadvantages of mechanical valves. Flex-
ible, trileaflet, biological tissue valves mimic their natural 
counterparts more closely than mechanical heart valves. 
10 Their central flow characteristics offer better hemodynamic 
efficiency, and their biological surfaces enhance thrombore-
sistance as compared to mechanical prostheses. 
The valves are chemically treated to make the tissue less 
15 immunogenic and thus less likely to incite an allergic or 
immunological reaction in the recipient. As a result, the tissue 
comprising the valve is non-viable, and therefore, subject to 
degeneration with time. Bioprosthetic valves are commonly 
employed in elderly patients for whom the risk of bleeding 
20 complications are high and in those whose desired way oflife 
precludes the discipline of anticoagulation therapy. 
The biological tissues are usually fixed with different 
chemicals (glutaraldehyde, Aminooleic acid, ethanol etc) and 
under different protocols in order to increase the durability of 
25 the valve. Leaflet fixation stiffens the tissue unintentionally, 
alters internal shear properties, increases shear stiffness, 
stress relaxation and hysteresis, and causes substantial dehy-
dration, all of which lead to valve failure due to calcification 
or tissue tearing. Although some chemical treatments are 
30 effective in reducing calcification, they do not prevent disrup-
tion of collagen fibers. Collagen fibers exposed to blood flow 
are damaged and cannot be repaired due to lack of viable cells 
within the leaflet. Therefore because of tissue degradation 
and calcification bioprosthetic valves have a limited durabil-A mechanical valve is a device constructed from man-
made materials and is used to replace patients damaged or 
diseased native heart valves. More than 60 percent of heart 
valve replacements have been made with mechanical pros-
theses due to their durability and superior hemodynamics 
which offer minimal resistance to flow. Despite their superior 
durability, the turbulent fluid mechanics of mechanical valves 
causes damage to blood cells. This damage to the blood cells 
can include thrombus formation. The possible thrombus for-
mation initiated by disturbed flow patterns necessitates life-
long anticoagulant therapy. Further problems are associated 
with mechanical heart valves, including small stagnant 45 
regions proximate the hinges that sometimes lead to bacterial 
infections causing further heart damage. 
35 ity which may average around 10 years. Although biopros-
thetic valve technology has advanced, their limited durability 
is a problem which may take a long time to address com-
pletely. 
Currently a new generation of bioprosthetic valves and 
40 mechanical valves is being developed, and these valves may 
be implanted percutaneously. While these bioprosthetic and 
mechanical valves present a number of improvements over 
the prior art, the safety and success of these devices is signifi-
cantly reduced by the complexity of their deployment. 
Many devices exist in the prior art, which attempt to 
address the complexity of properly deploying a bioprosthetic 
valve. For example, U.S. Pat. No. 6,790,230 to Beyersdorf et 
al. ("'230 patent'') discloses a conventional valve anchoring 
element, which has non-cylindrical form that corresponds to 
the shape of the aorta. The anchoring element of the '230 
patent is provided such that a replacement valve can be 
Many different valve designs with different materials of 
construction have evolved to address the deficiencies of 
mechanical valves, such as to reduce thrombus formation and 50 
decrease the mechanical stresses that can cause blood cell 
damage. Several synthetic polymers have been tested as leaf-
let materials such as silicone, polyolefin rubbers and polytet-
rafluoroethylene. Laboratory fatigue testing has illustrated 
that polyurethane valves are capable of achieving more than 
800 million cycles (-20 years of "normal" function). Valve 
leaflets constructed of a commercially available polyetheru-
rethane when implanted in sheep showed superior valve func-
tion to that of bioprosthetic valves. Thus, polymeric valves 
could offer a clinical advantage with the promise of improved 
durability compared to bioprostheses and low thrombogenic-
ity compared to mechanical valves. Although polymeric 
valves show great promise they have been under development 
for several decades and no design has made it to commercial-
ization due to failure or calcification within its normal bio-
logical environment. As a result, mechanical valves are still 
the primary choice for surgical correction and have to be used 
sutured to the interior of the anchoring element. The anchor-
ing element and associated replacement valve can then be 
delivered via a catheter to the aorta and expanded such as to 
55 disable the native aortic valve. Thereby, the expansion of the 
anchoring element in the aorta serves to disable the native 
aortic valve and, at the same time, enable the replacement 
valve. 
U.S. Pat. No. 7,018,406 to Seguin et al. ('"406 patent) 
60 discloses a prosthetic valve assembly to be used in replacing 
a deficient native valve. The prosthesis described in the '406 
patent includes a tissue valve supported on a self expandable 
stent. The prosthesis is capable of percutaneous delivery to 
the native valve, at which the prosthesis can be expanded and 
65 attached to the lumen wall. The '406 patent describes that the 
typical valve is made biological materials and is attached to 
the valve support band with a suture. The valve attached to the 
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valve support band is collapsible along its center axis so that 
the entire structure can be compressed and loaded onto a 
catheter for delivery. 
U.S. Patent Publication No. 2005/0137689 to Salahieh et 
al. ("'689 Publication") discloses a method for endovascu-
larly replacing a heart valve. The method disclosed in the '689 
Publication includes the steps of delivering a replacement 
valve and an expandable anchor in an unexpanded configu-
ration within a catheter to a vicinity of a heart valve. Once 
delivered to the proper location, the anchor is deployed from 10 
the catheter and expanded to contact tissue at an anchor site. 
The expansion of the anchor simultaneously deploys the col-
lapsed replacement heart valve contained within the anchor. 
The deployment of these conventional bioprosthetic valves 
requires the precise execution of a number of steps and tech- 15 
niques, and inaccurate execution of even one of these steps 
can lead to a patient fatality. For example, proper deployment 
of the bioprosthetic valve can require expansion of the valve 
anchor at a precise location within the native heart valve. 
Furthermore, the valve anchor must properly engage the 20 
lumen wall when expanded such that a good surface of con-
tact is made with the lumen wall to enable a tight contact. 
Good and safe seating of the valve anchor is critical, as it must 
withstand blood flow under high pressure, high velocity, and 
a significant amount of pulsation. Furthermore, a replacement 25 
valve positioned in an inadequately anchored valve will not 
be able to resist the forces of the constantly changing vessel 
wall diameter and turbulent blood flow. Improper and insuf-
ficient deployment can lead to migration of the valve anchor 
before or after the deployment of the bioprosthetic valve. 30 
Even the slightest migration of the valve anchor can have 
many detrimental results, including covering the openings to 
an arterial outlet or compromising the function of the replace-
ment valve. 
Not only is precise placement of the valve anchor of a 35 
bioprosthetic valve important, a secure seating of the valve 
anchor is critical because improper or insufficient deploy-
ment of the valve anchor can lead to leakage between the 
anchor and the lumen wall. It is often the case that a deficient 
native valve and areas of tissue around the native valve have 40 
6 
valve anchor could appear properly seated on the ultrasound 
image, but the side of the valve anchor not visible in the image 
could be misaligned and/or improperly sealed with the lumen 
wall. As described, a slightly improper seal or slight mis-
placement of the valve anchor can lead to catastrophic and 
even fatal results. Additionally, once the replacement valve 
has been fully deployed, it is difficult or impossible to change 
the position of the prosthesis without damaging the native 
structure. 
As a result of the limitations of both bioprosthetic heart 
valve and mechanical valves, patients have to choose between 
quality oflife and durability of the repair. Additionally there 
is a group of patients which may not tolerate the risks asso-
ciated with a mechanical valve, but may limit their lives using 
a bioprosthetic valve as a second operation to replace this 
valve can be considered clinically not viable. 
Therefore, it would be advantageous to provide an appara-
tus and method to prepare a deficient native valve for replace-
ment. 
Additionally, it would be advantageous to provide an appa-
ratus and method for accurate and efficacious deployment of 
a valve anchor. 
Additionally, it would be advantageous to provide an appa-
ratus and method for accurate and efficacious deployment of 
a valve anchor independent of a replacement heart valve. 
Additionally, it would be advantageous to provide an appa-
ratus and method for correcting valvular heart disease that 
allows for accurate and efficacious deployment of a heart 
valve prosthesis. 
Additionally, it would be advantageous to provide an appa-
ratus and method for correcting valvular heart disease that 
allows for viable methods to conduct repeat operations on a 
heart valve. 
Additionally, it would be advantageous to provide an appa-
ratus and method for correcting valvular heart disease that 
allows for viable methods to replace a previously deployed 
heart valve prosthesis. 
Additionally, it would be advantageous to provide an appa-
ratus and method for correcting valvular heart disease that 
allows for deployment of a replaceable heart valve prosthesis 
implemented in a minimally invasive marmer. irregularities and calcification that are a result of, or are con-
tributing factors to, the heart disease at issue. The typical 
calcification, thickening, and hardening of the cardiac annu-
lus can make it increasingly difficult to achieve proper sealing 
quality for the valve anchor of the bioprosthetic valve. For 
example, heavy calcification on the native valve can lead to 
bumpy and even surfaces, which can translate to a low quality 
seal of the valve anchor with the lumen wall if not deployed 
properly. Not only can calcification make it difficult to prop-
erly seat the valve anchor, fragments of the calcified deposits 
can be loosened during the seating of the valve anchor and 
thus enter blood stream causing damage and possible block-
age. 
Additionally, it would be advantageous to provide a releas-
ably connected heart valve prosthesis delivered with a long 
arm or steerable needle from outside the heart to a valve of a 
45 beating heart. 
Additionally, it would be advantageous to provide a 
smooth and substantially uniform surface within a lumen for 
deployment of a heart valve prosthesis. 
Additionally, it would be advantageous to provide a backup 
50 system capable of permitting a patient to go on bypass if a 
heart valve replacement procedure fails. 
While many of the conventional devices have attempted to 
address the issues and complexities associated with the mini- 55 
mally invasive deployment of a heart valve replacement, sig-
nificant problems and risks for the patient still exist. A large 
majority of the risk is due to the nature of the deployment of 
the replacement valves. Often, a surgeon has one shot to 
correctly deploy the heart valve prosthesis. Furthermore, the 60 
endovascular deployment of the heart valve provides a sur-
geon with a limited ability to verify the correctness and accu-
racy of the deployment. The surgeon's deployment of the 
replacement valve is often visually aided only by a two 
dimensional ultrasound image. This two dimensional image 65 
leaves a large amount of room for error in the three dimen-
sional deployment of the replacement valve. For example, the 
Additionally, it would be advantageous to provide an appa-
ratus capable of providing a separately deployable harbor for 
releasably connecting a heart valve prostheses. 
BRIEF SUMMARY OF THE INVENTION 
The present invention describes methods and apparatus to 
prepare a heart valve for replacement and improve a deficient 
heart valve. An exemplary embodiment of the method of 
preparing a heart valve for replacement involves delivering an 
anchoring conduit to a heart valve. The anchoring conduit is 
expanded in the heart valve and the expansion of the anchor-
ing conduit disables the heart valve. Furthermore, the expan-
sion of the anchoring conduit defines an open cavity. 
An exemplary embodiment of the method of improving a 
deficient heart valve involves delivering an anchoring conduit 
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to a heart valve. The anchoring conduit has a harbor, which is 
enabled to releasably connect a heart valve prosthesis. Then, 
a temporary valve is delivered in a condensed state to a target 
site in an artery proximate the heart valve. Subsequently, the 
anchoring conduit is deployed in the heart valve, disabling the 
heart valve. The temporary valve operates to temporarily 
replace the function of the heart valve when the anchoring 
conduit is expanded. 
8 
associated with bioprosthetic valves and long term durability 
associated with mechanical valves. Additionally, this proce-
dure can allow beating heart minimally invasive approaches 
which can benefit the clinical outcome of heart valve replace-
ments. 
These and other objects, features and advantages of the 
present invention will become more apparent upon reading 10 
the following specification in conjunction with the accompa-
nying drawing figures. 
An exemplary embodiment of the present invention pro-
vides a method of preparing a heart valve for replacement. 
The method involves the step of delivering an anchoring 
conduit to a heart valve. Subsequently, the anchoring conduit 
is expanded in the heart valve. Once the anchoring conduit 
has been expanded, it defines an open cavity. 
In an exemplary embodiment, the open cavity does not 
contain any leaflets or other elements of a heart valve pros-
thesis. Furthermore, in an exemplary embodiment, the open BRIEF DESCRIPTION OF THE FIGURES 
FIG.1 provides an illustration ofa normal aortic valve 101. 
FIG. 2 provides an illustration of an exemplary embodi-
ment of an anchoring conduit 200 implemented in aortic 
valve in accordance with an exemplary embodiment of the 
present invention. 
FIG. 3 provides an illustration of an exemplary embodi-
ment of anchoring conduit 200 and temporary valve 30S 
implemented in an aortic valve in accordance with an exem-
plary embodiment of the present invention. 
FIG. 4A provides an illustration of an exemplary embodi-
ment of a cardiac prosthetic system 400 implemented in aor-
tic valve in accordance with an exemplary embodiment of the 
present invention. 
FIG. 4B provides an illustration of an alternative embodi-
ment of a cardiac prosthetic system 400 implemented in aor-
tic valve in accordance with an exemplary embodiment of the 
present invention. 
FIG. SA provides an illustration of an exemplary embodi-
ment of an anchoring conduit 200 in accordance with an 
exemplary embodiment of the present invention. 
FIG. SB provides an illustration of an exemplary embodi-
ment of an anchoring conduit 200 in accordance with an 
exemplary embodiment of the present invention. 
FIG. 6 provides an illustration of an exemplary embodi-
ment of a temporary valve 30S in accordance with an exem-
plary embodiment of the present invention. 
FIG. 7 provides an illustration of an exemplary embodi-
ment of a heart valve prosthesis 420 in accordance with an 
exemplary embodiment of the present invention. 
FIG. 8 provides an illustration of an exemplary embodi-
ment of a cardiac prosthetic system 400 implemented in a 
pulmonic valve in accordance with an exemplary embodi-
ment of the present invention. 
DETAILED DESCRIPTION OF PREFERRED 
EMBODIMENTS 
The present invention addresses the deficiencies in the 
prior art by providing a minimally invasive apparatus and 
method for preparing a heart valve for replacement and for 
deploying a replaceable heart valve prosthesis. The apparatus 
and method of preparing a heart valve for replacement can be 
used to improve the success and efficacy of heart valve repair. 
The medical device and method ofimproving a deficient heart 
valve disclosed herein can be used to repeatedly deploy a 
heart valve prostheses within a deficient valve of the heart. 
Enabling the efficacious replacement of a heart valve can 
provide an effective manner of treating valvular heart disease 
without many of the drawbacks associated with conventional 
devices and methods. Significantly, the cardiac prosthesis 
system of the present invention provides a solution which 
does not force patients to choose between the quality of life 
15 cavity has a substantially uniform inner surface. The term 
substantially uniform is used herein to describe a surface that 
is generally uniform but may include certain undulations or 
features. For example, the term substantially uniform surface 
of the open cavity of the anchoring conduit could describe a 
20 cavity that includes a releasably engaging component. There-
fore, the substantially uniform surface of the cavity is gener-
ally uniform, but not entirely uniform in some embodiments. 
The smooth and substantially uniform inner surface of the 
exemplary embodiment of the expanded form of the anchor-
25 ing conduit provides a more safe and reliable surface on 
which to deploy a heart valve prosthesis. Typically, a deficient 
native valve and the areas of tissue around the native valve 
have irregularities and heavy calcification. The common cal-
cification, thickening, and hardening of the cardiac annulus 
30 can make it increasingly difficult to achieve proper sealing 
quality for a valve anchor. For example, the existing annulus 
of the deficient native valve can have a surface that is to 
varying degrees irregular and calcified, which not only less-
ens the quality of the support of the anchoring conduit but also 
35 acts as a source of leaks between the anchoring conduit and 
the valve annulus. The exemplary embodiment of the present 
invention can provide an anchoring conduit to aid in the 
placement of a heart valve prosthesis and overcome the com-
plexities associated with the irregular and calcified surface of 
40 a deficient valve annulus. The smooth and substantially uni-
form inner surface of the anchoring conduit, as opposed to the 
bumpy and calcified surface of native valve, can enable a 
more efficacious and reliable deployment of a replaceable 
heart valve. An exemplary embodiment of the anchoring con-
45 duit is capable of deployment independent of the deployment 
of the heart valve prosthesis. Furthermore, the quality of the 
seating of the anchoring conduit can be assessed and verified 
prior to the introduction of the heart valve prosthesis into the 
50 
patient's body. 
An exemplary embodiment of the present invention also 
provides a method of improving a deficient heart valve. The 
method first involves delivering an anchoring conduit to a 
heart valve. The anchoring conduit has a harbor, which is 
enabled to releasably connect a heart valve prosthesis. A 
55 temporary valve is delivered in a condensed state to a target 
site in an artery proximate the heart valve. The temporary 
valve can be expanded at the target site in the artery proximate 
the heart valve. Subsequently, the anchoring conduit can be 
expanded in the heart valve and the native components of the 
60 heart valve compress against the heart valve and disable the 
heart valve. The temporary valve can operate to temporarily 
replace the function of the heart valve when the anchoring 
conduit is expanded. 
Furthermore, the present invention enables a cardiac pros-
65 thetic system capable improving a deficient heart valve. In an 
exemplary embodiment, the deficient heart valve can either 
be a native valve in the heart or heart valve prosthesis previ-
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ously deployed in the heart. An exemplary embodiment of the 
cardiac prosthetic system in accordance with the present 
invention provides an anchoring conduit having a harbor. The 
harbor includes a first releasably engaging component. Fur-
thermore, the cardiac prosthetic system provides a temporary 
valve. Additionally, a heart valve prosthesis is provided, hav-
ing a second releasably engaging component enabled to be 
securely coupled and uncoupled from the first releasably 
engaging component of the harbor. 
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the deployment of a valve prosthesis. The independent 
deployment of the anchoring conduit 200 can help the sur-
geon avoid and minimize numerous risks involved in repair-
ing a deficient heart valve. Conventional devices involve the 
percutaneous deployment of one device containing both the 
valve anchor and the valve prosthesis. Most often, the surgeon 
conducting a minimally invasive procedure is visually aided 
only by the two-dimensional sonographic image of an ultra-
sound. Thus, the surgeon is faced with the task of attempting 
10 to precisely implement a three-dimensional device with only 
two-dimensional feedback. When using a conventional 
device, the surgeon essentially has "one shot" to perfectly 
deploy the device. 
FIG. 2 provides an illustration of an exemplary embodi-
ment of an anchoring conduit 200 implemented in an aortic 
valve in accordance with an exemplary embodiment of the 
present invention. As shown in FIG. 2, the anchoring conduit 
provides an expandable structure with a proximal anchor 
component 210 and a distal anchor component 215. In an 15 
exemplary embodiment, the expansion of the anchoring con-
duit 200 enables the proximal anchor component 210 and the 
distal anchor component 215 to interface with a tissue com-
ponent and define an open cavity 235 with a substantially 
uniform inner surface. 
The risks associated with the conventional "one shot" 
approach of percutaneous heart valve replacement are numer-
ous and alarming. Unfortunately, many procedures per-
formed with conventional devices have been unsuccessful 
and even fatal. A large risk associated with percutaneous 
deployment is that when the valve anchor of the conventional 
The terms proximal and proximate are used herein to 
describe a position which is in the relative vicinity of another 
position, including a range of vicinity positions through and 
including being directly adjacent or abutting another position. 
The term distal is used herein to describe a position which is 
situated a relative distance away from another position. Thus, 
the terms proximal/proximate and distal are used herein as 
spatial relation references and are not used to describe posi-
tions upstream or downstream in the flow of blood. 
20 device is implemented on the hardened and calcified surface 
of the native valve, it can be loosely seated. A relatively loose 
seating of the conventional valve device may ultimately lead 
to migration of the device or leakage between the device and 
the lumen wall. Moreover, an additional risk results from the 
25 fact that the placement of the conventional device can 
breakup the calcium deposits on the deficient heart valve and 
release these deposits into the bloodstream. All of these risks 
are associated with the deployment of a conventional valve 
device. An exemplary embodiment of the anchoring conduit 
30 200, however, can help to minimize and avoid a number of 
these risks. 
In the exemplary embodiment depicted in FIG. 2, the 
anchoring conduit 200 is deployed in an aortic valve 220. The 
anchoring conduit 200 can be delivered in unexpanded state, 
thereby enabling endovascular delivery or other minimally 
invasive forms of deployment. Thus, in an exemplary 
embodiment, the anchoring conduit 200 can be percutane- 35 
ously deployed via a catheter to the site of the aortic valve 
220. Once the surgeon, has delivered to the anchoring conduit 
200 in a collapsed state to the desired location within the 
aortic valve 220, the anchoring conduit 200 can then be 
expanded. It is this expansion of the anchoring conduit 200 40 
that causes the proximal anchor component 210 to engage the 
lumen wall within the aorta 225. In the exemplary embodi-
ment shown in FIG. 2, the anchoring conduit 200 is posi-
tioned such that the proximal anchor component 210 engages 
the aortic valve 220 proximate the arnmlus of the aortic valve 45 
220. In this marmer, the proximal anchor component 210 
serves to collapse the cusps of the aortic valve 220 against the 
lumen wall of the aorta 225. Thereby, the expansion of the 
anchoring conduit 200 may disable the native aortic valve 
220. 
The expansion of the anchoring conduit 200 also serves to 
engage the distal anchor component 215 with the lumen wall 
of the aorta 225. As shown in the exemplary embodiment of 
FIG. 2, the distal anchor component 215 can be positioned to 
engage the aorta 225 proximate the sinuses of the valsalva 
230. In an exemplary embodiment, the anchoring conduit 200 
can be configured to conform to the shape of the sinuses of the 
valsalva 230 and thus aid in locking the anchoring conduit 
200 into place. In an alternative embodiment, the distal 
anchor component 215 of the anchoring conduit 200 can be 
provided with hooks capable of piercing the lumen wall 
proximate the sinuses of the valsalva 230. The piercing of the 
lumen wall can aid in locking the anchoring conduit 200 in 
place. 
50 
Contrary to conventional devices, the anchoring conduit 
200 can contain only the anchoring components and inner 
lumen. The independent implementation of the anchoring 
conduit 200 permits the surgeon to concentrate on the vari-
ables involved in correctly and securely deploying the 
anchoring conduit 200 without concern for the placement or 
function of the replacement heart valve prosthesis. Therefore, 
the independent deployment of the anchoring conduit 200 can 
help to minimize the number of variables that the surgeon 
must control in deploying such a device. Furthermore, ifthe 
surgeon fails to correctly implement the anchoring conduit 
200, the surgeon can then implement certain procedures to 
correct the placement of the anchoring conduit 200 or extract 
the failed area where the anchoring conduit 200 was posi-
tioned. For example, and not limitation, should the placement 
of the anchoring conduit 200 fail, the patient can by placed on 
bypass and the failed aortic root can be replaced with an aortic 
root conduit. 
As shown in FIG. 2, when the anchoring conduit 200 is 
been deployed in the aortic valve 220, an open cavity 235 is 
created. This open cavity 235 can have a smooth and substan-
tially uniform surface. This smooth and substantially uniform 
surface can replace the calcified, hardened, and rough surface 
55 of the deficient aortic valve 220. The smooth and substantially 
uniform surface of the cavity 235 of the anchoring conduit 
200 provides many advantages. Significantly, the smooth and 
substantially uniform surface of the cavity provides a greatly 
improved area for deploying a heart valve prosthesis. Con-
60 ventional devices are often unsuccessful due to the necessity 
of anchoring the device on a non-uniform surface. Valve 
prosthesis deployed in accordance with an embodiment of the 
present invention can be enabled to be deployed on the sub-
stantially uniform inner surface of the anchoring conduit 200. 
An important advantage provided by an exemplary 65 
embodiment of the anchoring conduit 200 is that it can enable 
independent deployment of the valve anchor separate from 
In an exemplary embodiment the anchoring conduit 200 is 
composed of a thread-like structure that can be made of 
stainless steel, titanium, similar metals or metal alloys, or 
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suitable plastics. These thread-like structures or filaments can 
be latticed looped or wound. In one embodiment, the anchor-
ing conduit 200 composed of a surgical stainless steal mesh. 
In some embodiments, the anchoring conduit 200 is com-
posed of a shape memory material, such as a nickel-titanium 
alloy. The anchoring conduit 200 can be composed of a mate-
rial capable of bending into the surface of the lumen wall 
against which it is anchored. As the native inner lumen is 
often an irregular and hard surface, is advantageous for the 
anchoring conduit 200 to be enabled to bend and conform to 
the shape of the native lumen wall against which it is anchored 
so as to ensure safe and secure seating of the anchoring 
conduit 200. Additionally, an embodiment of the anchoring 
conduit 200 may include a biocompatible lumen. In this 
embodiment, the thread-like structure provides the outer core 
and its hollow interior can be lined with a biocompatible 
lumen. In some embodiments, the anchoring conduit 200 can 
provide an outer layer capable of bending to conform to the 
native lumen wall, and an inner layer which maintains a 
substantially uniform and smooth surface. 
12 
present invention. As shown in FIG. 4A, the anchoring con-
duit 200 can be deployed in the aortic root proximate the 
aortic annulus. In an exemplary embodiment, the anchoring 
conduit 200 covers the inlet area between the left ventricle 
430 and the aorta 225. In one embodiment, the anchoring 
conduit 200 can cover an area immediately proximate the 
aortic annulus 405. 
In an exemplary embodiment shown in FIG. 4A, the 
anchoring conduit 200 can delivered in a condensed form. For 
10 example, and not limitation, the anchoring conduit 200 can be 
composed of a surgical stainless mesh that is capable of being 
collapsed. The collapsed anchoring conduit 200 is capable of 
delivery in a minimally invasive manner, including via per-
cutaneous deployment or a long arm delivery device. In an 
15 exemplary embodiment, an anchoring conduit 200 is deliv-
ered minimally invasively through a heart chamber or the 
arterial/venous system into the aortic root 410. Once the 
collapsed anchoring conduit 200 is delivered to the desired 
location in the base of the aortic root 410 it can be expanded 
20 and anchored into the aortic root 410. In an exemplary 
embodiment, the anchoring conduit 200 can be expanded 
proximate the aortic annulus 405. In another embodiment, the 
anchoring conduit 200 can be expanded further into the aortic 
root 410. Additionally, in an alternative embodiment, the 
In alternative embodiments to that depicted in FIG. 2, the 
anchoring conduit 200 can be deployed in other areas of the 
aorta 225. For example, and not limitation, the anchoring 
conduit 200 can be expanded such that the proximal anchor 
component 210 of the anchoring conduit 200 interfaces with 
the lumen wall of the aorta 225 proximate the sino-tubular 
junction. Therefore, the anchoring conduit 200 can be 
deployed further down on the aortic root. Additionally, the 
anchoring conduit 200 can be deployed further up the aorta, 
such as above the sinuses of the valsalva 230 or even proxi- 30 
mate the aortic arch. Additionally, the anchoring conduit 200 
can be deployed in valves other than aortic valve. In an exem-
plary embodiment, the anchoring conduit 200 can be 
deployed in a pulmonic valve. 
25 steps of the methods of the present invention can be imple-
mented via a remote device. For example, and not limitation, 
a surgeon could be enabled to use a remote device to expand 
the anchoring conduit 200 once delivered to the desired posi-
tion. 
In an exemplary embodiment, the anchoring conduit 200 
provides a harbor 415. The harbor 415 can include a releas-
ably engaging component, which is enabled to serve as a 
receiving port for a heart valve prosthesis. This releasably 
engaging component, in an exemplary embodiment, is 
enabled to couple with a mating releasably engaging compo-
nent of heart valve prosthesis 420. The heart valve prosthesis 
FIG. 3 provides an illustration of an exemplary embodi- 35 
ment of anchoring conduit 200 and temporary valve 305 
implemented in an aortic valve in accordance with an exem-
plary embodiment of the present invention. As shown in FIG. 
3, the anchoring conduit 200 can be deployed in the aortic 
valve 220 such that the aortic valve 220 is disabled. More 40 
420 can be a variety of different types of heart valve prosthe-
ses, including various types of mechanical valves and bio-
prosthetic heart valves. 
The implementation of the anchoring conduit 200 renders 
the native valve non-functional, therefore, an exemplary 
embodiment of the present invention provides a temporary 
valve that can be placed in the aorta 225 to perform the 
function of the native valve. The temporary valve 305, in the 
particularly, the expansion of the anchoring conduit 200 
serves to collapse the cusps of the native aortic valve 220 and 
thus it ceases to function. In an exemplary embodiment of the 
present invention, a temporary valve 305 can be implemented 
to temporarily replace the function of this disabled heart 
valve. 
45 exemplary embodiment shown in FIG. 4A, can be a mechani-
cal or bioprosthetic valve. The temporary valve 305 can be 
deployed in a minimally invasive manner, such as attached to 
a catheter 310 shown FIG. 4A. Therefore, the temporary 
valve 305 can be delivered before the native valve is rendered 
The temporary valve 305, in the exemplary embodiment 
shown in FIG. 3, can be a mechanical or bioprosthetic valve. 
The temporary valve 305 can be deployed in a minimally 
invasive manner, such as attached to a catheter 310 shown 50 
FIG. 3. The temporary valve 305 can be initially collapsed 
while it is delivered to its functional location. When the tem-
porary valve 305 is in its functional location, it can then be 
expanded. When the temporary valve 305 expands, it is 
pushed or sealed against the lumen wall of the aorta 225. In an 
exemplary embodiment the temporary valve 305 does not 
attach to the wall of the aorta 225. Once the temporary valve 
305 is expanded, its cusps can open and close controlling the 
flow ofblood through the aorta 225. Therefore, the temporary 
valve 305 can be delivered before the native valve is rendered 
non-functional. Thus, once the native valve is rendered non-
functional, the temporary valve 305 can perform the function 
of the native valve without interrupting the cardiac cycle of 
the beating heart. 
FIG. 4A provides an illustration of an exemplary embodi-
ment of a cardiac prosthetic system 400 implemented in aor-
tic valve in accordance with an exemplary embodiment of the 
non-functional. Once the native valve is rendered non-func-
tional, the temporary valve 305 can perform the function of 
the native valve without interrupting the cardiac cycle of the 
beating heart being repaired. 
When both the anchoring conduit 200 and the temporary 
55 valve 305 are in place, the heart valve prosthesis 420 can be 
introduced into the heart. In an exemplary embodiment 
shown in FIG. 4A, the heart valve prosthesis 420 is introduced 
through a port 425 in the heart chamber. In an alternative 
embodiment, the heart valve prosthesis 420 can be introduced 
60 through the venous/arterial system. The port 425 in the exem-
plary embodiment depicted in FIG. 4A is mounted on the 
lower wall of the left ventricle 430 and provides an orifice 
through which the heart valve prosthesis 420 can be deliv-
ered. Those of skill in the art will appreciate that port 425 
65 could be a variety of different ports know in the art. The heart 
valve prosthesis 420 can be delivered via a catheter or long 
arm device, or other minimally invasive apparatus. The heart 
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valve prosthesis 420 of the exemplary embodiment shown 
FIG. 4A is delivered via long arm device 43S. 
In the exemplary embodiment depicted in FIG. 4A, once 
the heart valve prosthesis 420 has been introduced into the left 
ventricle 430, it can be delivered to a harbor 41S on the 5 
anchoring conduit 200. In an exemplary embodiment, the 
heart valve prosthesis 420 includes a plurality ofleaflets 440. 
These leaflets 440 can function to replace the action of defi-
cient heart valve. Additionally, the heart valve prosthesis 420 
provides an annulus ring 44S. The annulus ring 44S is capable 10 
of interfacing with the anchoring conduit 200 to provide a 
proper seal for the heart valve prosthesis 420. The heart valve 
prosthesis 420 may be stented or stentless according to needs 
of particular implementation. 
In an exemplary embodiment, the heart valve prosthesis 15 
420 can provide a releasably engaging component. This 
releasably engaging component is enabled to couple and 
uncouple to a mating releasably engaging component pro-
vided on harbor 41S. The releasably engaging component of 
the heart valve prosthesis 420 can be positioned at various 20 
locations on the device to ensure proper mating with the 
harbor 41S. This releasably engaging component may be on 
the annulus or stent portion of the heart valve prosthesis 420. 
Once the heart valve prosthesis 420 has been mated to the 
releasably engaging component of the harbor 41S of the 25 
anchoring conduit 200, the harbor 41S can releasably retain 
the heart valve prosthesis 420 in place, and the heart valve 
prosthesis 420 can be released from the catheter or long arm. 
After heart valve prosthesis 420 is deployed, the temporary 
valve 30S can be extracted. Furthermore, the ports in the 30 
venous/arterial system or ports in the heart can be closed 
using a mechanism which can allow them to be opened when 
the heart valve needs to be replaced. 
When a heart valve prosthesis 420 fails or reaches a limit in 
it functional life, the ports in the arterial/venous system and 35 
the heart chambers can be reopened to deliver a new heart 
valve prosthesis to the harbor 41S in the anchoring conduit 
200. Again, a temporary valve 30S can be placed in the aorta 
22S to control blood flow. Then, a catheter or long arm can be 
used to engage the old heart valve prosthesis 420 on the 40 
anchoring conduit 200. The heart valve prosthesis 420 can 
then be uncoupled from the releasably engaging component 
of the harbor 41S and the old heart valve prosthesis 420 can be 
extracted. A new heart valve prosthesis can subsequently be 
introduced into the left ventricle 430, via a catheter or long 45 
arm mechanism, and releasably engaged to the harbor 41S of 
anchoring conduit 200. Thus, the deficient heart valve pros-
thesis can be replaced with a new heart valve prosthesis in a 
minimally invasive manner. The above process may be 
repeated one or several times over the life of the patient 50 
according to clinical requirements. 
FIG. 4B provides an illustration of an alternative embodi-
ment of a cardiac prosthetic system 400 implemented in aor-
tic valve in accordance with an exemplary embodiment of the 
present invention. In the alternative embodiment depicted in 55 
FIG. 4B, the heart valve prosthesis 420 is delivered via a 
conduit in the temporary valve 30S. In the alternative embodi-
ment shown in FIG. 4B, the temporary valve 30S is delivered 
via an enlarged catheter 4SO which provides an internal con-
duit 4SS. The internal conduit 4SS enables a path through 60 
which a heart valve prosthesis 420 can be delivered in accor-
dance with an exemplary embodiment of the cardiac pros-
thetic system 400. 
As shown in FIG. 4B, the alternative embodiment of the 
heart valve prosthesis 420 is enabled to passed through the 65 
center of the temporary valve 30S. Thereby, in accordance 
with a method of improving a deficient heart valve of the 
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present invention, the temporary valve 30S can be deployed to 
temporarily perform the function of the deficient aortic valve 
220. The anchoring conduit 200 can then be properly seated 
and secured within the deficient aortic valve as shown in FIG. 
4B. After it is verified that the anchoring conduit 200 has been 
properly placed, the heart valve prosthesis 420 can then be 
delivered to the aorta 22S via the internal conduit 4SS of the 
enlarged catheter 4SO. In an exemplary embodiment, the heart 
valve prosthesis 420 is capable of delivery in a collapsed 
form, such that it can be passed through the internal conduit 
4SS. Once the heart valve prosthesis 420 has entered the aorta 
22S, it can be expanded into functional form. Thereafter, the 
heart valve prosthesis 420 can be deployed in the anchoring 
conduit 200. 
In the embodiment depicted in FIG. 4B, a releasably 
engaging component on the heart valve prosthesis 420 can be 
coupled to a mating releasably engaging component on the 
harbor 41S of the anchoring conduit 200. In an alternative 
embodiment, the heart valve prosthesis 420 can be provided 
without a releasably engaging component. In this alternative 
embodiment, the heart valve prosthesis 420 can simply be 
expanded within the anchoring conduit 200 such that the 
annulus 44S of the heart valve prosthesis 420 interfaces with 
the smooth inner surface of the anchoring conduit 200. Those 
of skill in the art will appreciate that the heart valve prosthesis 
420 could be delivered and deployed in a number of different 
manners without detracting from the scope of the invention. 
An additional alternative embodiment of the cardiac pros-
thetic system 400 enables an alternative method for the deliv-
ery of the anchoring conduit 200. In this embodiment, the 
anchoring conduit 200 is enabled to be delivered through the 
internal conduit 4SS of the enlarged catheter 4SO shown in 
FIG. 4B. Thus, the method of improving a deficient heart 
valve implemented with this embodiment can first involve the 
delivery and deployment of the temporary valve 3SO to an 
area proximate the deficient heart valve. Next, the anchoring 
conduit 200 can be permitted to pass through the internal 
conduit 4SS of the enlarged catheter 4SO of the deployed 
temporary valve 30S. Thus, the anchoring conduit 200 can be 
delivered by catheter in a compressed state through the tem-
porary valve 30S. The anchoring conduit 200 can then be 
positioned proximate the deficient heart valve and deployed. 
After the anchoring conduit 200 is successfully deployed, the 
catheter that delivered the anchoring conduit 200 can be 
removed. Subsequently, a heart valve prosthesis 420 can be 
delivered through the internal conduit 4SS of the enlarged 
catheter 4SO of the deployed temporary valve 30S. 
FIG. SA provides an illustration of an exemplary embodi-
ment of an anchoring conduit 200 in accordance with an 
exemplary embodiment of the present invention. The anchor-
ing conduit 200 has a proximal anchor component 210 and a 
distal anchor component 21S. The proximal anchor compo-
nent 210 can be anchored into a lumen wall. In the exemplary 
embodiment depicted in FIG. SA, the proximal anchor com-
ponent 210 has a flared edge which serves as a seal preventing 
leaks between the aortic root and the walls of the anchoring 
conduit 200. In an exemplary embodiment, the distal anchor-
ing edge 21S is contoured to the shape of the sinuses of the 
valsalva 230. In this exemplary embodiment, the distal 
anchoring edge 21S is configured to engage the surface of the 
sinuses of the valsalva 230 and further secure the anchoring 
conduit 200 into place. 
Additionally, the exemplary embodiment of the anchoring 
conduit 200 shown in FIG. SA provides tissue piercing com-
ponents SOS and SlO. The tissue piercing components SOS 
and Sl 0 are enabled to pierce and engage a tissue component, 
and, thus, aid in stabilizing the anchoring conduit 200. In the 
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exemplary embodiment shown in FIG. SA, the piercing com-
ponents SOS and Sl 0 of the distal anchor component 220 flare 
into the sinuses ofvalsalva and help to secure the anchoring 
conduit 200 into place. Those of skill in the art will appreciate 
that the piercing components SOS and SlO can be hooks or 
other types ofanchors sufficient to engage a tissue component 
in the heart. The expansion into the sinuses may have a lumen 
in order to prevent blood migration between the conduit and 
the aortic wall. In an exemplary embodiment, the anchoring 
200 provides an outer surface for mating with the irregulari-
ties of the surface to which the anchoring conduit 200 is 
seated and a substantially uniform inner surface. Thereby, the 
smooth and substantially uniform inner surface of the anchor-
ing conduit 200 is not effected by the undulations impressed 
in the seated outer surface of the anchoring conduit 200. 
As shown in FIG. SA, and exemplary embodiment of the 
anchoring conduit 200 can provide a releasably engaging 
component SlS. The releasably engaging component SlS can 
be many suitable components capable of enabling the cou-
pling and uncoupling of a heart valve prosthesis 420. The 
releasably engaging component SlS shown in the exemplary 
embodiment in FIG. SA is comprised of threading. Thus, the 
proximal anchor component 210 can provide a series of 
threading for the releasably engaging component SlS. Cou-
pling of the heart valve prosthesis 420 can then be accom-
plished, in the exemplary embodiment, by attaching a mating 
releasably engaging component of the heart valve prosthesis 
420 with appropriate counter threading. Therefore, the 
method of improving a deficient heart valve in accordance 
with the present invention can involve the coupling of heart 
valve prosthesis 420 to the threading of the releasably engag-
ing component SlS of the anchoring conduit 200. Those of 
skill in the art will appreciate that number of different devices, 
components, and mechanisms could be substituted for the 
threading of the releasably engaging component SlS shown 
in FIG. SA without detracting from the invention. For 
example, and not limitation, the releasably engaging compo-
nent SlS could be a series of groves in which mating prongs 
can be inserted, an orifice through which an expanding toggle 
component can be inserted, a magnetic system, clamps, a 
latching mechanism, or other suitable component. 
FIG. SB provides an illustration of an exemplary embodi-
ment of an anchoring conduit 200 in accordance with an 
exemplary embodiment of the present invention. In the exem-
plary embodiment depicted in FIG. SB, the anchoring conduit 
200 traverses the sinuses of the valsalva 230. As previously 
described in relation to FIG. 1, the sinuses ofthevalsalva 230 
are located just above the three cusps, 1 OS, 110, and llS (FIG. 
1) and each sinus corresponds to each individual cusp. Proxi-
mate the sinuses of the valsalva 230 are the origins of the 
coronary arteries. The anchoring conduit 200 can provide 
openings proximate the sinuses of the valsalva so as not to 
interrupt the openings to the coronary arteries and allow for 
the free flow ofblood. In the exemplary embodiment shown in 
FIG. SB, the distal anchor component 21S of the anchoring 
conduit 200 may also extend beyond the sinuses of valsalva 
230 and anchor into the aortic wall below the aortic arch, as 
shown in FIG. SB. 
In the exemplary embodiment shown in FIG. SB, an exter-
nal aortic ring S20 may be releasably placed on the external 
surface of the aortic root in order to aid in locking the anchor-
ing conduit 200 in place. In this embodiment, the distal 
anchor component 210 of anchoring conduit 200 protrudes 
radially outward against the lumen wall. The aortic ring S20 
can then deployed below the protrusions in the distal anchor 
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component 3SO of the anchoring conduit 200, and thereby 
prevent the anchoring conduit 200 from migrating past the 
aortic ring S20. 
The exemplary embodiment of the anchoring conduit 200 
shown in FIG. SB provides a proximal anchor component 
210. The proximal end 210 can contain a harbor 41S. The 
harbor 41S can enable the releasable connection of a heart 
valve prosthesis. The harbor 41S in the exemplary embodi-
ment in FIG. SB is placed on the proximal anchor component 
1 o 210 of the anchoring conduit 200. In another embodiment, the 
harbor 41S may be located in the normal position of the native 
valve. In an alternative embodiment, the harbor 41S can be 
located in the distal anchor component 21S of the anchoring 
conduit 200. The harbor 41S can provide a releasably engag-
15 ing component. Those of skill in the art will appreciate that 
many different types of releasably engaging components 
could be incorporated into the harbor 41S to accomplish the 
necessary function. 
FIG. 6 provides an illustration of an exemplary embodi-
20 ment of a temporary valve 30S in accordance with an exem-
plary embodiment of the present invention. The temporary 
valve 30S is includes a single or plurality of leaflets within a 
collapsible frame. In the exemplary embodiment shown in 
FIG. 4, the leaflets 60S can be constructed ofbiocompatible 
25 materials. In a non-limiting example, a biocompatible poly-
mer material is used to create the leaflets 60S. In an alternative 
embodiment, the leaflets 60S of the temporary valve 30S can 
be constructed from bovine pericardium. In yet another 
embodiment, the leaflets 60S of the temporary valve 30S can 
30 be constructed from porcine aortic leaflets. Additionally, the 
leaflets 60S of the temporary valve 30S can be constructed 
from metallic materials such as carbon or other metals. Those 
of skill in the art will appreciate that the temporary valve 30S 
can be a number of different types of valves capable ohem-
35 porary deployment into the heart. 
In the exemplary embodiment depicted in FIG. 4, the col-
lapsible frame 610 of the temporary valve 30S may be con-
structed of a biocompatible polymer structure. In another 
embodiment, the collapsible frame 610 may be constructed 
40 using a doughnut shaped balloon, where the balloon is con-
structed of a polymer. Alternatively, an embodiment of the 
collapsible frame 610 may be constructed of a memory alloy 
or memory polymer mesh. 
As shown in FIG. 6, the collapsible frame 610 can be 
45 attached to a polymer catheter 61S for delivery to the desired 
location within the heart. Typically the collapsible frame 610 
is permanently connected to the catheter 310, as it is not 
necessary to release the collapsible frame 610 from the cath-
eter 310. The catheter 310 enables a surgeon to maintain 
50 control over the function and location of the temporary valve 
30S. Moreover, the catheter 310 can cause the collapsible 
frame 610 and leaflets 60S to collapse under direct control of 
the surgeon. For example, and not limitation, if the anchoring 
conduit is to be positioned in the native aortic valve, the 
55 temporary valve 30S can be endovascularly delivered via 
catheter 310 to a position proximate the native aortic valve in 
the aorta. Thus, the temporary valve 30S can be expanded and 
deployed to replace the function of the native aortic valve 
before the anchoring conduit renders the native aortic valve 
60 nonfunctional. 
FIG. 7 provides an illustration of an exemplary embodi-
ment of a heart valve prosthesis 420 in accordance with an 
exemplary embodiment of the present invention. The heart 
valve prosthesis 420 in its preferred embodiment is a biopros-
65 thetic valve. The heart valve prosthesis 420 includes a single 
or plurality ofleaflets 70S. In an exemplary embodiment, the 
leaflets 70S may be constructed of treated tissue, such as but 
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not limited to, bovine pericardium or aortic leaflet material. In 
other embodiments the leaflets 705 may be constructed of a 
biocompatible polymer. 
As shown in FIG. 7, the heart valve prosthesis 420 can have 
an annulus 710. The annulus 710 may be constructed of 
biocompatible metals or polymers. Additionally, as shown in 
FIG. 7, the heart valve prosthesis 420 has a releasably engag-
ing component 715. The releasably engaging component 715 
18 
the heart chamber. The port 820 in the exemplary embodi-
ment depicted in FIG. 8 is mounted on the lower wall of the 
right ventricle 810 and provides an orifice through which the 
heart valve prosthesis 420 can be delivered. In the exemplary 
embodiment depicted in FIG. 8, once the heart valve prosthe-
sis 420 has been introduced into the right ventricle 810, it can 
be delivered to a harbor 415 on the anchoring conduit 200. 
In an exemplary embodiment, the heart valve prosthesis 
420 can provide a releasably engaging component enabled to is enabled to be coupled to the releasably engaging compo-
nent of harbor 415. Thereby, the releasably engaging compo-
nent 715 of the heart valve prosthesis 420 can be securely 
attached to the harbor 415. In an exemplary embodiment 
shown in FIG. 7, the releasably engaging component 715 of 
the heart valve prosthesis 420 is threading, which can be 
provided on the side of the heart valve prosthesis 420. The 
threading of the releasably engaging component 715 can 
couple to counter-threading of the releasably engaging com-
ponent 515 (FIG. SA) of the anchoring conduit 200. Those of 
skill in the art will appreciate that the releasably engaging 
component 715 may be many other suitable components 
including, but not limited to, a screw, magnetic, clamps or 
latching systems which can releasably engage the heart valve 
prosthesis 420 with the harbor 415. 
10 couple to a mating releasably engaging component provided 
on harbor 415. Once the heart valve prosthesis 420 has been 
mated to the releasably engaging component of the harbor 
415 of the anchoring conduit 200, the harbor 415 can releas-
ably retain the heart valve prosthesis 420, and the heart valve 
15 prosthesis 420 can be released from the catheter or long arm. 
After heart valve prosthesis 420 is in place, the temporary 
valve 305 can be extracted. Furthermore, the ports in the 
venous/ arterial system or ports in the heart can be closed in an 
manner that can allow them to be opened if the heart valve 
20 needs to be replaced. Thereby, should the first heart valve 
prosthesis deployed become deficient, a second heart valve 
prosthesis can be replaced for the first. 
The heart valve prosthesis 420 can also be enabled to 
connected to a catheter or long arm which may be used to 
deliver the arm to a specific location. In its preferred embodi-
ments the catheter or long arm device which releasably 
attaches a heart valve prosthesis 420 into the harbor 415, may 
While the invention has been disclosed in its preferred 
forms, it will be apparent to those skilled in the art that many 
25 modifications, additions, and deletions can be made therein 
without departing from the spirit and scope of the invention 
and its equivalents as set forth in the following claims. 
be constructed of a biocompatible polymer or metal. The long 
arm device has distal and proximal ends. In the distal end, the 30 
catheter or long arm device has a locking component which 
may releasably hold a heart valve prosthesis 420. This locking 
component may be a screw, clamp, latching system, or many 
other suitable components. On the proximal end, the long arm 
device or catheter contains a control component which can 35 
allow the release or coupling of a heart valve. Additionally the 
long arm device or catheter is controllably flexible in other to 
direct the heart valve prosthesis 420 to the desired location. 
FIG. 8 provides an illustration of an exemplary embodi-
ment of a cardiac prosthetic system 400 implemented in a 40 
pulmonic valve in accordance with an exemplary embodi-
ment of the present invention. As shown in FIG. 8, the anchor-
ing conduit 200 can be deployed in the pulmonary artery 815 
proximate the pulmonic valve 805. In an exemplary embodi-
ment, the anchoring conduit 200 covers the inlet area between 45 
the right ventricle 810 and the pulmonary artery 815. In one 
embodiment, the anchoring conduit 200 can be implemented 
in an area immediately proximate the pulmonic valve 805. In 
alternate embodiment, the anchoring conduit 200 can be 
implemented over a larger portion of the pulmonary artery 50 
815. Those of skill in the art will appreciate that the dimen-
sions and placement location of the anchoring conduit 200 
can be modified in a variety of embodiments without detract-
ing from the scope of the invention. 
In an exemplary embodiment, the anchoring conduit 200 55 
provides a harbor 415. The harbor 415 can include a releas-
ably engaging component, which is enabled to serve as a 
receiving port for a heart valve prosthesis 420. The imple-
mentation of the anchoring conduit 200 renders the native 
pulmonic valve 805 non-functional, therefore, an exemplary 60 
embodiment of the present invention provides a temporary 
valve 305 that can be placed in the pulmonary artery 815 to 
perform the function of the native pulmonic valve 805. 
When both the anchoring conduit 200 and the temporary 
valve 305 are in place, the heart valve prosthesis 420 can be 65 
introduced into the heart. In an exemplary embodiment, the 
heart valve prosthesis 420 is introduced through a port 820 in 
What is claimed is: 
1. A method of preparing a heart valve for replacement 
comprising: 
delivering an anchoring conduit to a heart valve, the 
anchoring conduit comprising an expandable structure 
having an outer layer and an inner layer, the outer layer 
configured to bend to conform to the contour of a tissue 
component and the inner layer comprising a smooth and 
substantially uniform inner surface; 
wherein the expansion of the expandable structure enables 
the expandable structure to interface with the tissue 
component and define an open cavity, the open cavity 
defined at least in part by the inner layer having the 
smooth and substantially uniform inner surface; 
wherein the anchoring conduit includes a harbor enabled to 
releasably connect a heart valve prosthesis; and 
expanding the anchoring conduit in the heart valve. 
2. The method of preparing a heart valve for replacement of 
claim 1 further comprising: 
delivering a temporary valve, in a condensed state, to a 
target site proximate the heart valve; and 
deploying the temporary valve at the target site proximate 
the heart valve; and 
wherein the temporary valve operates to temporarily 
replace the function of the heart valve when the anchor-
ing conduit is expanded. 
3. The method of preparing a heart valve for replacement of 
claim 1, wherein the open cavity of the anchoring conduit 
provides an inner lumen surface against which a heart valve 
prosthesis can be deployed. 
4. The method of preparing a heart valve for replacement of 
claim 1, wherein the inner surface of the open cavity includes 
a biocompatible lumen. 
5. An anchoring conduit comprising: 
an expandable structure having an outer layer and an inner 
layer, the outer layer configured to bend to conform to 
the contour of a tissue component and the inner layer 
comprising a smooth and substantially uniform inner 
surface; 
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wherein the expansion of the expandable structure enables 
the expandable structure to interface with the tissue 
component and define an open cavity, the open cavity 
defined at least in part by the inner layer having the 
smooth and substantially uniform inner surface; and 
wherein the anchoring conduit, further comprises a harbor 
in communication with the expandable structure, the 
harbor including a first releasably engaging component. 
6. The anchoring conduit of claim 5, wherein the anchoring 
conduit further comprises an anchoring component config- 10 
ured to disable a heart valve. 
7. The anchoring conduit of claim 5, wherein the anchoring 
conduit further comprises an anchoring component config-
ured to disable a native heart valve by compressing the com-
ponents of the native heart valve against the native heart 15 
valve. 
8. The anchoring conduit of claim 5, wherein an anchoring 
component is configured to receive a heart valve prosthesis. 
9. The anchoring conduit of claim 8, wherein the expand-
able structure is configured to enable tissue growth onto the 20 
heart valve prosthesis. 
10. The anchoring conduit of claim 5, wherein an anchor-
ing component is enabled to be endovascularly delivered. 
11. The anchoring conduit of claim 5, wherein a heart valve 
prosthesis having a second releasably engaging component is 25 
enabled to be securely coupled and uncoupled from the first 
releasably engaging component of the harbor. 
12. The anchoring conduit of claim 11, wherein the heart 
valve prosthesis can be coupled and uncoupled from the first 
releasably engaging component of the harbor within the 30 
heart. 
13. The anchoring conduit of claim 5, wherein the expand-
able structure is configured to contain a plurality of debris 
released from the tissue component. 
14. The anchoring conduit of claim 5, wherein the expand- 35 
able structure is configured to expand and adapt to the geom-
etry of the sinuses of the valsalva. 
15. The anchoring conduit of claim 5, wherein the anchor-
ing conduit can be delivered through the apex of a heart. 
20 
of the heart valve prosthesis to the first releasably engaging 
component of the anchoring conduit. 
22. The method of improving a valve competency of claim 
21, further comprising: 
removing the heart valve prosthesis from the anchoring 
conduit; and 
deploying a second heart valve prosthesis in the open cav-
ity of the anchoring conduit. 
23. A method of improving a deficient heart valve compris-
ing: 
delivering the anchoring conduit of claim 5 to a heart valve; 
delivering a temporary valve, in a condensed state, to a 
target site proximate the heart valve; 
deploying the temporary valve at the target site proximate 
the heart valve; and 
deploying the anchoring conduit in the heart valve, the 
deployment of the anchoring conduit disabling the heart 
valve; and 
wherein the temporary valve operates to temporarily 
replace the function of the heart valve when the anchor-
ing conduit is expanded. 
24. The method of improving a deficient heart valve of 
claim 23, further comprising: 
delivering the heart valve prosthesis to an area in the heart 
proximate the anchoring conduit; and 
coupling the heart valve prosthesis to the harbor of the 
anchoring conduit. 
25. The method of improving a deficient heart valve of 
claim 24, further comprising removing the temporary valve. 
26. The method of improving a deficient heart valve of 
claim 25, further comprising: 
delivering a temporary valve, in a condensed state, to a 
target site in an artery proximate the heart valve; 
expanding the temporary valve at the target site in the 
artery proximate the heart valve; 
decoupling the heart valve prosthesis from the harbor of the 
anchoring conduit; 
delivering a second heart valve prosthesis to an area in the 
heart proximate the anchoring conduit; and 
coupling the second heart valve prosthesis to the harbor of 
the anchoring conduit. 
16. The anchoring conduit of claim 5, wherein the expand- 40 
able structure comprises a proximal anchor component and a 
distal anchor component. 27. The method of improving a deficient heart valve of 
claim 26, further comprising removing the temporary valve. 
28. The method of improving a deficient heart valve of 
45 claim 24, wherein the temporary valve and the heart valve 
prosthesis are endovascularly delivered. 
17. The anchoring component of claim 16, wherein the 
proximal anchor component and the distal anchor component 
are configured to interface with the tissue component. 
18. A method of improving a valve competency compris-
ing: 
providing the anchoring conduit of claim 5 to an area 
proximate a heart valve, wherein the harbor is enabled to 
releasably connect a heart valve prosthesis; 
deploying the anchoring conduit, the deployment of the 
anchoring conduit defining the open cavity; and 
deploying a heart valve prosthesis in the open cavity of the 
anchoring conduit. 
50 
19. The method of improving a valve competency of claim 55 
18, wherein deploying the heart valve prosthesis involves 
expanding the heart valve prosthesis within the open cavity of 
the anchoring conduit. 
20. The method of improving a valve competency of claim 
18, wherein the anchoring conduit provides a first releasably 60 
engaging component and the heart valve prosthesis provides 
a second releasably engaging component enabled to be 
securely coupled and uncoupled from the first releasably 
engaging component of the anchoring conduit. 
21. The method of improving a valve competency of claim 65 
20, wherein deploying the heart valve prosthesis involves 
securely coupling the second releasably engaging component 
29. The method of improving a deficient heart valve of 
claim 28, wherein the heart valve prosthesis can be delivered 
through a conduit in the temporary valve. 
30. The method of improving a deficient heart valve of 
claim 23, wherein the heart valve is an aortic valve. 
31. The method of improving a deficient heart valve of 
claim 23, wherein the heart valve is a pulmonic valve. 
32. A cardiac prosthetic system comprising: 
the anchoring conduit of claim 5; a temporary valve; and 
a heart valve prosthesis having a second releasably engag-
ing component enabled to be securely coupled and 
uncoupled from the first releasably engaging component 
of the harbor. 
33. The cardiac prosthetic system of claim 32, further 
comprising a second heart valve prosthesis, the second heart 
valve prosthesis having a third releasably engaging compo-
nent enabled to be coupled and uncoupled from the first 
releasably engaging component of the harbor. 
34. The cardiac prosthetic system of claim 32, wherein the 
anchoring conduit is enabled to be deployed in an aortic heart 
valve. 
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35. The cardiac prosthetic system of claim 32, wherein the 
anchoring conduit is enabled to be deployed in a pulmonic 
heart valve. 
36. The cardiac prosthetic system of claim 32, wherein the 
anchoring conduit is enabled to be delivered through a blood 5 
vessel. 
37. The cardiac prosthetic system of claim 32, wherein the 
temporary valve is enabled to temporarily perform the func-
tion of a heart valve. 
38. The cardiac prosthetic system of claim 32, wherein the 10 
temporary valve and the heart valve prosthesis are endovas-
cularly delivered. 
39. The cardiac prosthetic system of claim 38, wherein the 
heart valve prosthesis can be delivered through a conduit in 
the temporary valve. 15 
40. A cardiac device comprising: 
a heart valve prosthesis having a releasably engaging com-
ponent; and 
the anchoring conduit of claim 5; wherein the releasably 
engaging component is enabled to be connected to the 20 
harbor located within a heart. 
41. The cardiac device of claim 40, wherein the releasably 
engaging component of the harbor is capable of being 
coupled to the releasably engaging component of the heart 
valve prosthesis. 25 
42. The cardiac device of claim 40, wherein the heart valve 
prosthesis is enabled to be released from its connection to the 
harbor located within the heart. 
* * * * * 
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